The FDA conducts investigation of the benefits of Plavix in some patients.
Wired PR News.com – The Food and Drug Administration (FDA) has begun an investigation on whether Plavix, a blood thinner used to reduce heart attack and stroke risks, has less benefit for certain patients. As reported by the Associated Press (AP), the second best selling drug in the world has been reported to possibly be less effective for patients taking certain types of medications for heartburn. The agency is also noted to be in the process of reviewing whether there is a genetic correlation between the drug’s effectiveness and patients.
Elizabeth Baxter, spokesperson for Plavix marketer Sanofi-Aventis, is quoted in the AP report as stating, “Individuals do not all respond to the same degree to a specific drug… Many studies are currently ongoing, including studies of clopidogrel, to explore what is responsible for this phenomenon.”
Photo Credit: Trounce